Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical company that has been simplifying complex medical challenges for over 150 years. The company focuses on developing, manufacturing, and distributing specialty pharmaceutical products and therapies. Mallinckrodt serves a diverse range of clients, including healthcare providers, hospitals, and patients, primarily in the United States and Europe. The company operates in the specialty pharmaceuticals market, which involves the production of drugs that treat rare and complex conditions. Mallinckrodt's business model revolves around research and development, manufacturing, and sales of its pharmaceutical products. The company generates revenue through the sale of its specialty drugs and therapies, which are often used to treat conditions such as autoimmune diseases, rare diseases, and critical care conditions. Mallinckrodt is committed to advancing environmental, social, and governance (ESG) initiatives, as highlighted in its 2022 Sustainability Report. The company's core values include being patient-centric, maintaining integrity, fostering innovation, and promoting collaboration. These values guide Mallinckrodt's efforts to improve the health and well-being of patients worldwide.

Keywords: specialty pharmaceuticals, rare diseases, autoimmune diseases, critical care, research and development, manufacturing, healthcare providers, patient-centric, innovation, ESG initiatives.